Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1223342 | 0.98 | GNAO1 (0.37) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL3562028 | 0.86 | — | — | |
| SCHEMBL3020121 | 0.86 | CHRM1 (0.43) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL5830706 | 0.86 | — | — | |
| SCHEMBL4239877 | 0.85 | GNAO1 (0.43) | CHRM1GNAO1GNAI3GNAI1 | |
| SCHEMBL9741247 | 0.83 | GNAO1 (0.46) | CHRM1GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL27157910 | 0.83 | GNAO1 (0.46) | CHRM1GNAO1GNAI3GNAI1 | |
| SCHEMBL20487794 | 0.83 | GNAO1 (0.46) | CHRM1GNAO1GNAI3GNAI1 | |
| Trifluoroacetic Acid SCHEMBL6135632 | 0.82 | ITGB3 (0.34) | SLC6A2SLC6A4 | |
| SCHEMBL684437 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | claimed |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-116669722-A | Interleukin-1 receptor-related kinase (IRAK) degradants and uses thereof | 凯麦拉医疗公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | disclosed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | disclosed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | SLC6A2 750/4885HTR2A 194/4885HTR2C 161/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | SLC6A2 395/4885HTR2A 36/4885HTR2C 35/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | SLC6A2 822/4885HTR2A 163/4885HTR2C 83/4885 |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | SLC6A2 3723/4885HTR2A 3748/4885HTR2C 1451/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | SLC6A2 822/4885HTR2A 163/4885HTR2C 83/4885 |
| US-20020177559-A1 | Quinolone derivatives | ABCB11, ABCB1, ABCG2 | SLC6A2 198/4885HTR2A 3059/4885HTR2C 2879/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | SLC6A2 2637/4885HTR2A 2068/4885HTR2C 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.